The Dales Report – Why Psychedelic Treatments Will Benefit Investors and Healthcare
Is Drug Repurposing the new breakthrough for faster …
Radius Research Interview – Algernon NeuroScience Initiates TBI Research Program with DMT
CEO Christopher J. Moreau provides an update on …
Proactive Investors CEO Interview – Algernon NeuroScience completes first dosing in Phase 1 clinical study of DMT
Algernon Pharmaceuticals CEO Christopher J. Moreau joined …
SR Times – “Drug Could Possibly Both Reduce Acute Damage of the Stroke” – How DMT Could be the Future of Stroke Treatment
“Drug Could Possibly Both Reduce Acute Damage of the …
Radius Research Interview – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau – Ifendprodil Program Update Targeting Chronic Cough
Radius Research Interview – Algernon Pharmaceuticals …
Radius Research – Algernon Pharma (AGN) CEO Chris Moreau – AP-188 DMT Dimethyltryptamine Program Update
Radius Research – Algernon Pharma (AGN) CEO Chris Moreau …
Benzinga – A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Canadian clinical-stage psychedelics company Algernon …
Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as it Sounds
Microdose: Microdosing DMT to Treat Stokes: Not as Trippy as …
Proactive Investors CEO Interview – Algernon NeuroScience Doses First Patient in Stroke Study
Proactive Investors CEO Interview – Algernon NeuroScience Doses …
The Market Herald – Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic Cough Study of Ifenprodil
Algernon Pharmaceuticals Announces Upcoming Phase 2b Chronic …
Proactive Investors Interview – Algernon Pharmaceuticals Releases Details of Planned Phase 2b Chronic Cough Study of Ifenprodil
Proactive Investors Interview – Algernon Pharmaceuticals …
Benzinga – Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Psychedelic Subsidiaries News: Blackhawk Spins Out Three …
Proactive Investors Interview – Algernon Pharmaceuticals Forms Algernon NeuroScience Subsidiary to Advance DMT Stroke Program
Proactive Investors Interview – Algernon Pharmaceuticals …
Wonderland 2022 Recap: Algernon Pharmaceuticals
Wonderland 2022 Recap: Algernon Pharmaceuticals With Wonderland still …
The National Investor – Repurposing Drugs For New Needs — Algernon Pharmaceuticals Inc. (CSE-AGN; OTCQB-AGNPF)
I first was introduced to Algernon roughly a year ago. When I …
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon for Algernon Pharmaceuticals DMT Study
Psychedelic Therapeutics For Human Stroke: Participant Screening …
MarketOne Video Interview with CEO Christopher J. Moreau – Algernon Pharmaceuticals is the First to Investigate DMT as a Treatment for Stroke
MarketOne Video Interview with CEO Christopher J. Moreau – …
Psychedelic Finance – Feature: Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Feature: Christopher J. Moreau | Chief Executive Officer, Algernon …
Drug Discovery and Development – Why Algernon Believes it is the Janis Joplin of Psychedelic Medicine Companies
Drug Discovery and Development – Why Algernon Believes it is …
Psychedelic Finance – Feature: Algernon Pharmaceuticals
Feature: Algernon Pharmaceuticals Who: Algernon …
Market One – Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 Study of DMT for Stroke
Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 …
Born2Invest – Algernon Pharmaceuticals Is Developing Pioneering Treatments With a Cost-Efficient R&D Pipeline
Algernon Pharmaceuticals Is Developing Pioneering Treatments With a …
BNN Bloomberg – In a sector ripe for revival, Algernon’s development pipeline positions it well.
In a sector ripe for revival, Algernon’s development pipeline …
Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale Clinical Trial for DMT Phase 2 Depression Study
Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Yale …
Psychedelic Spotlight – Prolonged DMT Infusions could be a Breakthrough for Stroke Patients
Prolonged DMT Infusions could be a Breakthrough for Stroke Patients …
Drug Discovery and Development – DMT pioneer Rick Strassman weighs in on psychedelic hope and hype
DMT pioneer Rick Strassman weighs in on psychedelic hope and hype …
High TImes – New Research Exploring DMT as a Treatment for Stroke
High TImes – New Research Exploring DMT as a Treatment for …
Radius Research – Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business Update – Ifenprodil & DMT Trials
Algernon Pharmaceuticals (AGN) CEO Christopher J. Moreau: Business …
Mugglehead Magazine – Algernon receives approval to conduct DMT study in the Netherlands
Algernon receives approval to conduct DMT study in the Netherlands …
Pulmonary Fibrosis News – Orphan Drug Status Sought for NP-120 to Treat IPF With Cough
Algernon Pharmaceuticals has filed for orphan drug status for …
Proactive Investors Interview – Algernon Pharmaceuticals Gains Approval for Phase 1 Clinical Study of DMT for Treatment of Stroke
Algernon Pharmaceuticals CEO Christopher Moreau joined …
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Streetwise Reports – Will Pharma Co. Keep Pushing Higher After …
Proactive Investors Interview – Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough
Proactive Investors Interview – Algernon Pharmaceuticals …
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co.
Streetwise Reports – Hedge Fund Doubles Position in Biotech Co. …
MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs
Since covering Algernon 6 months ago, the biotech sector has …
Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
Most idiopathic pulmonary fibrosis (IPF) patients treated …